Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.07M | $4.80M | $1.18M | $0.00 | $0.00 | — | — | — |
| Revenue growth | — | 132.0% | -75.4% | -100.0% | — | — | — | — |
| Operating income | -$13.7M | -$19.2M | -$43.7M | -$83.6M | -$127M | -$170M | -$142M | -$104M |
| Operating margin | -662.0% | -400.0% | -3694.0% | — | — | — | — | — |
| Net income | -$13.7M | -$19.2M | -$45.7M | -$83.5M | -$123M | -$161M | -$135M | -$102M |
| Net margin | -664.3% | -401.2% | -3869.7% | — | — | — | — | — |
| EPS (diluted) | -$6.33 | -$7.56 | -$2.76 | -$2.07 | -$3.03 | -$3.74 | -$2.58 | -$1.90 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.2M | -$14.2M | -$38.3M | -$68.1M | -$89.2M | -$130M | -$122M | -$84.1M |
| Capital expenditures | $653K | $353K | $31.0K | $666K | $1.43M | $1.27M | $447K | $212K |
| Free cash flow | -$13.8M | -$14.6M | -$38.3M | -$68.8M | -$90.7M | -$132M | -$122M | -$84.4M |
| Share buybacks | $6.00K | — | — | — | — | — | — | — |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8.26M | $9.02M | $434M | $364M | $48.8M | $22.4M | $17.6M | $16.4M |
| Total assets | — | $10.7M | $436M | $380M | $306M | $243M | $148M | $59.0M |
| Total liabilities | — | $11.0M | $6.21M | $17.1M | $43.0M | $52.8M | $34.2M | $33.1M |
| Long-term debt | — | $5.42M | — | — | $9.39M | $9.64M | $9.47M | $4.53M |
| Shareholders' equity | -$51.8M | -$70.6M | $430M | $363M | $263M | $190M | $114M | $26.0M |
| Retained earnings | — | -$72.8M | -$119M | -$202M | -$325M | -$486M | -$621M | -$723M |
| Shares (wtd avg diluted) | 2.75M | 3.08M | 18.5M | 40.3M | 40.7M | 43.0M | 52.2M | 53.7M |
Every figure is extracted from ALX ONCOLOGY HOLDINGS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.